Somatostatin analogs for malignant bowel obstruction resulting from peritoneal carcinomatosis.

摘要

To the Editor: An article recently published in Journal of Clinical Oncology by Mariani et al described a randomized, double-blind trial of a single dose of sustained-release lanreotide 30 mg versus a placebo for the symptomatic treatment of patients with inoperable bowel obstruction as a result of peritoneal carcinomatosis. We appreciate the difficulties of conducting a trial in this patient population and applaud the efforts of the study group investigators, who collaborated across 22 centers for 5 years to accrue 80 patients. Evidence-based evaluation of treatments for the symptomatic management of malignant bowel obstruction (MBO) continues to be an important area of research.